Prelude Therapeutics (PRLD) Gains from Sales and Divestitures (2019 - 2026)

Prelude Therapeutics has disclosed Gains from Sales and Divestitures across 8 years of filings, most recently posting $59557.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $59557.0, up 535.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $59557.0 (up 535.27% YoY), and the FY2025 annual result was $37500.0, down 11.76% from the prior year.
• Gains from Sales and Divestitures came in at $59557.0 for Q1 2026 at Prelude Therapeutics, up from $37500.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $386476.0 in Q4 2022 to a low of $1250.0 in Q1 2023.
• The 5-year median for Gains from Sales and Divestitures is $40000.0 (2023), against an average of $85000.2.
• Across the five-year window, Gains from Sales and Divestitures plunged 98.71% in 2023 and surged 750.0% in 2024, its largest moves.
• Prelude Therapeutics' Gains from Sales and Divestitures stood at $386476.0 in 2022, then sank by 84.15% to $61250.0 in 2023, then tumbled by 30.61% to $42500.0 in 2024, then decreased by 11.76% to $37500.0 in 2025, then jumped by 58.82% to $59557.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $59557.0 (Q1 2026), $37500.0 (Q4 2025), and $28125.0 (Q3 2025), per Business Quant data.